News Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN’s Digital Advisory Board to Speak at Annual ePharma Summit

Board to Describe How Pharma Can Look Beyond Healthcare for Best Practices in Digital Communications

NEW YORK--(BUSINESS WIRE)--Feb. 2, 2012-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that its Digital Advisory Board, an esteemed group of digital thought-leaders both in and outside of healthcare, is participating in the eleventh annual ePharma Summit, a conference showcasing healthcare industry experts’ views on the evolution of digital marketing and how to reach consumers and physicians through social and digital media. A POZEN-sponsored panel discussion titled, “Transforming the Pharma Industry – Breakthrough Perspectives from Digital Leaders,” will be held on Tuesday, February 7, 2012 from 10:50 – 11:25 a.m. at the Sheraton New York Hotel & Towers.

“POZEN and its Digital Advisory Board are excited to be among the distinguished attendees speaking at this prominent digital marketing event,” said Liz Cermak, Executive Vice President and Chief Commercial Officer, POZEN Inc., and moderator of the discussion. “Comprised of some of the most influential voices and thought-leaders in the digital and social media space, our board will share their diverse perspectives and experiences and offer valuable insight into how pharmaceutical companies can leverage new digital strategies to more effectively engage physician and patient audiences.”

During the session, the Digital Advisory Board members will share their experiences, offering their perspectives on how to evolve traditional pharmaceutical marketing to best meet the needs of target audiences. The Digital Advisory Board has been working alongside POZEN as it prepares for the launch and marketing of its lead compound PA32540, which is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. They have helped POZEN design the actual Launch Plan for the brand.

About the Digital Advisory Board

POZEN, a progressive, specialty pharmaceutical company, formed the Digital Advisory Board to help advance the Company’s vision of creating a new pharma commercial model.

POZEN’s Digital Advisory Board members include:

  • Raj Amin, Chief Executive Officer and Co-Founder, HealthiNation
  • Bonin Bough, Senior Director of Digital and Social Media, PepsiCo
  • Marc Monseau, Founder and Principal, MDM Communications
  • Daniel Palestrant, MD, Chief Executive Officer and Founder, Par8o, former SERMO Founder
  • Meredith Ressi, President, Manhattan Research

POZEN’s goal in collaborating with these Advisors is to look beyond the pharmaceutical industry to leverage best practices as well as identify untapped digital strategies that will help shape plans to deliver affordable, accessible medicines to customers.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN is currently seeking strategic partners to help maximize the opportunity for its portfolio assets.

The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

About PA

POZEN is creating a portfolio of integrated aspirin therapies - the PA product platform. The products in the PA portfolio are intended to significantly reduce GI ulcers and other GI complications compared to taking aspirin alone.

The first candidate is PA32540. It is a coordinated-delivery tablet combining immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin. This novel, patented product is administered orally once a day and will be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers. POZEN has completed enrollment for the long-term safety study and the two pivotal studies, targeting a New Drug Application filing in 3Q12.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on GlaxoSmithKline for the sales and marketing of Treximet® and our dependence on AstraZeneca for the sales and marketing of VIMOVO™; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended September 30, 2011. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Source: POZEN Inc.

POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Stephanie Bonestell, 919-913-1030
Manager, Investor Relations & Public Relations


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.